ProCE Banner Activity

Overview, Rationale, and Guidance on Testing for Rare Genomic Alterations in Advanced Thyroid Cancer

Slideset Download

Download these slides from a live symposium at ASCP 2022 featuring guidance from a pathologist on best practices for biomarker testing in advanced thyroid cancer along with the latest clinical evidence on targeted therapies available for the treatment of RET-altered and BRAF V600E–positive disease.

Released: September 13, 2022

Share

Faculty

Juan C. Hernandez-Prera

Juan C. Hernandez-Prera, MD

Associate Member
Department of Pathology
Section Head
Head & Neck - Endocrine Pathology
Department of Pathology
Moffitt Cancer Center
Tampa, Florida

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

Supported by an educational grant from Bayer Healthcare Pharmaceuticals Inc, Blueprint Medicines and Genentech, a member of the Roche Group, and Lilly.

Bayer HealthCare Pharmaceuticals Inc.

Blueprint Medicines and Genentech, a member of the Roche Group

Lilly

Partners

American Society for Clinical Pathology

ProCE Banner

Partnered with the American Society for Clinical Pathology.

Faculty Disclosure

Primary Author

Juan C. Hernandez-Prera, MD

Associate Member
Department of Pathology
Section Head
Head & Neck - Endocrine Pathology
Department of Pathology
Moffitt Cancer Center
Tampa, Florida

Juan C. Hernandez-Prera, MD, has no relevant conflicts of interest to report.